CLINICAL TRIALS PROFILE FOR DOXYCYCLINE

505(b)(2) Clinical Trials for DOXYCYCLINE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00694694 ↗	Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.	Completed	National Institute for Medical Research, Tanzania	Phase 3	2008-06-01	This trial sets out to determine whether the combination of azithromycin and artesunate (AZ+AS) is as good as the current standard treatment for uncomplicated malaria in Tanzania, artemether-lumefantrine (AL). There are two reasons this is important 1. there are only a limited range of drug combinations which work against malaria in this area of Tanzania 2. azithromycin has antimalarial properties, but is also a broad-spectrum antibiotic, so if the combination is an effective antimalarial it might have a place where there are no diagnostic facilities as syndromic treatment for fever. Artesunate and azithromycin have both been used alone or in combination with other drugs in children in Tanzania for many years, and are considered safe. There is trial evidence for the effectiveness of this combination in adults in Asia, as well as in-vitro (laboratory) evidence that it works against the malaria parasite. The trial randomizes children with non-severe malaria to the new combination AZ+AS or the standard care arm AL. The primary outcome is the parasitological failure rate by day 28- meaning do malaria parasites get cleared, and stay cleared for at least 28 days. Secondary outcomes include safety.
New Combination	NCT00694694 ↗	Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.	Completed	London School of Hygiene and Tropical Medicine	Phase 3	2008-06-01	This trial sets out to determine whether the combination of azithromycin and artesunate (AZ+AS) is as good as the current standard treatment for uncomplicated malaria in Tanzania, artemether-lumefantrine (AL). There are two reasons this is important 1. there are only a limited range of drug combinations which work against malaria in this area of Tanzania 2. azithromycin has antimalarial properties, but is also a broad-spectrum antibiotic, so if the combination is an effective antimalarial it might have a place where there are no diagnostic facilities as syndromic treatment for fever. Artesunate and azithromycin have both been used alone or in combination with other drugs in children in Tanzania for many years, and are considered safe. There is trial evidence for the effectiveness of this combination in adults in Asia, as well as in-vitro (laboratory) evidence that it works against the malaria parasite. The trial randomizes children with non-severe malaria to the new combination AZ+AS or the standard care arm AL. The primary outcome is the parasitological failure rate by day 28- meaning do malaria parasites get cleared, and stay cleared for at least 28 days. Secondary outcomes include safety.

All Clinical Trials for DOXYCYCLINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000403 ↗	Doxycycline and OA Progression	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1996-09-01	This study will determine whether doxycycline decreases the severity or rate of progression of osteoarthritis (OA) in the knee. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most popular agents used to treat OA, but elderly women, in whom OA is especially common, are at greatest risk of developing serious side effects from NSAIDs. Our study targets overweight middle-aged women who have OA in one knee. Half of the 432 study participants will receive the treatment (doxycycline) and half will receive a placebo (inactive pill). Treatment with doxycycline (or placebo) will last 30 months, and participants and researchers will not know who is receiving doxycycline and who is receiving placebo until the end of the study. We will look for narrowing of the joint space in the knee that was not affected by OA at the start of the study. Joint space narrowing is a sign of OA. We will also use questionnaires to evaluate participants' symptoms and functioning.
NCT00000403 ↗	Doxycycline and OA Progression	Completed	National Institute on Aging (NIA)	Phase 3	1996-09-01	This study will determine whether doxycycline decreases the severity or rate of progression of osteoarthritis (OA) in the knee. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most popular agents used to treat OA, but elderly women, in whom OA is especially common, are at greatest risk of developing serious side effects from NSAIDs. Our study targets overweight middle-aged women who have OA in one knee. Half of the 432 study participants will receive the treatment (doxycycline) and half will receive a placebo (inactive pill). Treatment with doxycycline (or placebo) will last 30 months, and participants and researchers will not know who is receiving doxycycline and who is receiving placebo until the end of the study. We will look for narrowing of the joint space in the knee that was not affected by OA at the start of the study. Joint space narrowing is a sign of OA. We will also use questionnaires to evaluate participants' symptoms and functioning.
NCT00000403 ↗	Doxycycline and OA Progression	Completed	Indiana University	Phase 3	1996-09-01	This study will determine whether doxycycline decreases the severity or rate of progression of osteoarthritis (OA) in the knee. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most popular agents used to treat OA, but elderly women, in whom OA is especially common, are at greatest risk of developing serious side effects from NSAIDs. Our study targets overweight middle-aged women who have OA in one knee. Half of the 432 study participants will receive the treatment (doxycycline) and half will receive a placebo (inactive pill). Treatment with doxycycline (or placebo) will last 30 months, and participants and researchers will not know who is receiving doxycycline and who is receiving placebo until the end of the study. We will look for narrowing of the joint space in the knee that was not affected by OA at the start of the study. Joint space narrowing is a sign of OA. We will also use questionnaires to evaluate participants' symptoms and functioning.
NCT00000938 ↗	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	Lyme disease is the most common tick-borne disease in the United States. It is caused by the spirochete Borrelia burgdorferi. It may exist in a chronic form and be the result of: 1) persistent infection by B. burgdorferi; 2) damage caused by the original infectious process; or 3) the presence of coinfection with another organism transmitted by Ixodes ticks. The purpose of this study is to determine the safety and effectiveness, in seronegative patients, of intensive antibiotic treatment in eliminating symptoms of Chronic Lyme Disease (CLD).
NCT00001101 ↗	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	Lyme disease is the most common tick-borne disease in the United States. It is caused by the spirochete Borrelia burgdorferi. It may exist in a chronic form and be the result of: 1) active infection by B. burgdorferi; 2) damage caused by the original infectious process; or 3) the presence of co-infection with another organism transmitted by Ixodes ticks. The purpose of this study is to determine the safety and effectiveness, for seropositive patients, of intensive antibiotic treatment in eliminating symptoms of Chronic Lyme Disease (CLD).
NCT00002872 ↗	Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions	Completed	National Cancer Institute (NCI)	Phase 3	1996-11-01	RATIONALE: Some drugs such as bleomycin or doxycycline, or other compounds like talc, may help to control fluid in the chest caused by cancer. It is not yet known if bleomycin, doxycycline, or talc is more effective in treating patients with malignant pleural effusions. PURPOSE: Randomized phase III trial to compare the effectiveness of bleomycin, doxycycline, or talc in treating patients with malignant pleural effusions.

Clinical Trial Conditions for DOXYCYCLINE

Condition Name

Condition Name for DOXYCYCLINE
Intervention	Trials
Acne Vulgaris	20
Rosacea	10
Syphilis	9
Acne	9

Condition MeSH

Condition MeSH for DOXYCYCLINE
Intervention	Trials
Infections	31
Acne Vulgaris	28
Infection	26
Communicable Diseases	25

Clinical Trial Locations for DOXYCYCLINE

Trials by Country

Trials by Country for DOXYCYCLINE
Location	Trials
United States	441
Canada	28
France	22
China	18
Egypt	13

Trials by US State

Trials by US State for DOXYCYCLINE
Location	Trials
California	36
New York	34
Texas	26
Pennsylvania	25
Florida	22

Clinical Trial Progress for DOXYCYCLINE

Clinical Trial Phase

Clinical Trial Phase for DOXYCYCLINE
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	2
PHASE2	9

Clinical Trial Status

Clinical Trial Status for DOXYCYCLINE
Clinical Trial Phase	Trials
Completed	197
Recruiting	75
Unknown status	35

Clinical Trial Sponsors for DOXYCYCLINE

Sponsor Name

Sponsor Name for DOXYCYCLINE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	16
University Medical Centre Ljubljana	10
University of Washington	10

Sponsor Type

Sponsor Type for DOXYCYCLINE
Sponsor	Trials
Other	553
Industry	101
NIH	49

Doxycycline: Clinical Trial Landscape, Market Dynamics, and Future Projections

Last updated: February 19, 2026

Doxycycline, a broad-spectrum tetracycline antibiotic, is a cornerstone therapy for various bacterial infections. This report analyzes its current clinical trial activity, market performance, and future market projections, with a focus on its established and emerging indications.

What are the Current Clinical Trial Trends for Doxycycline?

The current clinical trial landscape for doxycycline demonstrates activity across multiple therapeutic areas, with a significant focus on its anti-inflammatory and dermatological applications, alongside its established antimicrobial role. Research is investigating its efficacy in conditions beyond its primary bacterial infection indications, exploring its potential in chronic inflammatory diseases and oncology.

Key Therapeutic Areas Under Investigation

• Dermatology: Acne vulgaris remains a primary area of clinical investigation, with trials evaluating novel formulations and combination therapies to improve efficacy and reduce side effects.
  • Acne Vulgaris: Numerous Phase II and III trials are ongoing, exploring extended-release formulations and lower-dose regimens for chronic management. Companies are seeking to optimize treatment protocols and address patient compliance [1].
  • Rosacea: Doxycycline, particularly in sub-antimicrobial doses, is a focus for trials investigating its anti-inflammatory properties in managing moderate to severe rosacea. Studies aim to confirm efficacy in reducing inflammatory papules and pustules [2].
• Infectious Diseases: While a mature market, new trials continue to explore doxycycline's role in specific or emerging infectious disease threats, including antimicrobial resistance patterns and novel delivery methods.
  • Lyme Disease: Research is exploring shorter treatment durations and prophylactic use in high-risk populations. The increasing incidence of Lyme disease in endemic regions drives continued investigation [3].
  • Malaria Prophylaxis: Doxycycline is a well-established option for malaria prophylaxis, and ongoing trials may seek to refine dosage regimens and assess its effectiveness against emerging resistant strains in specific geographical areas.
• Oncology: Emerging research is investigating doxycycline's potential as an adjunct in cancer therapy, leveraging its anti-inflammatory and potential anti-angiogenic properties.
  • Cancer Adjunct Therapy: Early-stage trials are exploring doxycycline in combination with chemotherapy or immunotherapy for various cancers, including pancreatic and ovarian cancers. The rationale centers on its ability to modulate the tumor microenvironment and suppress inflammation associated with tumor growth [4].
• Other Inflammatory Conditions:
  • Rheumatoid Arthritis: Exploratory studies are assessing the anti-inflammatory effects of sub-antimicrobial doses of doxycycline in managing rheumatoid arthritis, focusing on joint inflammation and disease progression markers [5].
  • Periodontal Disease: Trials continue to examine the use of doxycycline in managing chronic periodontitis, utilizing its anti-collagenase activity to reduce tissue destruction.

Notable Clinical Trial Milestones and Approvals

The regulatory landscape for doxycycline is largely characterized by established approvals for its antimicrobial indications. Recent activity has focused on reformulating existing doxycycline products and exploring new indications based on its anti-inflammatory properties.

• FDA Approvals: Doxycycline has a long history of FDA approvals for a wide range of bacterial infections. Recent regulatory focus has been on new formulations or specific dose adjustments for existing indications.
• New Formulations: Development of extended-release and immediate-release formulations designed to improve patient compliance and reduce gastrointestinal side effects is a recurring theme in clinical development.
• Sub-Antimicrobial Dose Approvals: The approval of doxycycline at sub-antimicrobial doses for rosacea has paved the way for further research into its anti-inflammatory mechanisms in other chronic conditions.

Geographic Distribution of Trials

Clinical trials for doxycycline are distributed globally, with a significant concentration in North America and Europe due to robust research infrastructure and established regulatory frameworks. Asia is also emerging as a significant region for clinical research.

What is the Current Market Landscape for Doxycycline?

The global doxycycline market is mature and characterized by a high degree of generic competition. Its broad spectrum of activity and established safety profile ensure consistent demand across both human and veterinary applications. The market is segmented by formulation, indication, and end-user.

Market Size and Growth Rate

The global doxycycline market was valued at approximately USD 1.5 billion in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.5% to 4.5% through 2030 [6]. This moderate growth is driven by an increasing prevalence of bacterial infections, the growing demand for veterinary antibiotics, and the expanding use of doxycycline in non-antimicrobial applications.

Key Market Segments

• By Formulation:
  • Oral Formulations: Tablets and capsules dominate the market, accounting for over 70% of sales.
  • Injectable Formulations: Used for severe infections or when oral administration is not feasible, these hold a smaller market share.
  • Topical Formulations: Primarily for dermatological applications like acne.
• By Indication:
  • Infectious Diseases: Respiratory tract infections, urinary tract infections, and sexually transmitted infections remain the largest segments.
  • Dermatology: Acne vulgaris and rosacea represent significant and growing segments.
  • Veterinary Medicine: Doxycycline is widely used to treat bacterial infections in livestock and companion animals.
• By End-User:
  • Hospitals: Major consumers due to the prevalence of serious infections.
  • Retail Pharmacies: Drive demand for outpatient treatment of common infections.
  • Veterinary Clinics and Farms: Contribute significantly to the overall market.

Major Players and Competitive Landscape

The doxycycline market is highly fragmented with numerous generic manufacturers. Key global players include, but are not limited to, Teva Pharmaceutical Industries, Mylan N.V. (now Viatris), Pfizer Inc., and numerous regional generic drug manufacturers. The competitive landscape is characterized by price sensitivity and a focus on efficient manufacturing and supply chain management.

• Teva Pharmaceutical Industries: A leading global generic pharmaceutical company with a broad portfolio including doxycycline.
• Viatris Inc. (formerly Mylan N.V.): Offers a wide range of generic antibiotics, including doxycycline.
• Pfizer Inc.: While a major innovator, Pfizer also participates in the generic market with established doxycycline products.
• Sun Pharmaceutical Industries Ltd.: A significant global player in generics with a strong presence in emerging markets.
• Sandoz (a division of Novartis): A major global player in the biosimil and generic medicines.

Pricing Trends and Reimbursement

Doxycycline is a cost-effective antibiotic, contributing to its widespread use. Generic competition has led to significant price erosion for many standard formulations. Reimbursement policies vary by region but generally favor cost-effective treatments for common infections. The development of new formulations or indications may command higher price points initially.

Impact of Antimicrobial Resistance

The growing global concern over antimicrobial resistance (AMR) poses both a challenge and an opportunity for doxycycline. While resistance to certain bacteria is increasing, doxycycline's broad spectrum and established efficacy against many common pathogens continue to make it a first-line option. Research into its use in combination therapies or for specific resistant strains is ongoing.

What are the Market Projections for Doxycycline?

The market projections for doxycycline indicate continued stable growth, driven by its persistent utility in established indications and the expansion of its applications into chronic inflammatory diseases and oncology. The generic nature of the drug means growth will largely be volume-driven and influenced by factors like global health trends and new therapeutic research.

Future Market Growth Drivers

• Increasing Prevalence of Bacterial Infections: Global population growth and evolving healthcare access are expected to maintain demand for antibiotics.
• Expansion into Non-Antimicrobial Indications: Research into doxycycline's anti-inflammatory and anti-angiogenic properties for conditions like rosacea, rheumatoid arthritis, and certain cancers is a significant future growth driver, potentially leading to new market segments and higher-value products.
• Veterinary Applications: The expanding global meat industry and increasing pet ownership will continue to fuel demand for veterinary antibiotics, including doxycycline.
• Cost-Effectiveness: As a mature, off-patent drug, doxycycline remains an economically attractive treatment option, especially in price-sensitive markets.
• Advancements in Formulations: Development of improved delivery systems, such as extended-release tablets or novel topical applications, can enhance patient adherence and expand market reach.

Potential Challenges and Risks

• Antimicrobial Resistance: Continued emergence and spread of bacterial resistance to tetracyclines could limit doxycycline's effectiveness and necessitate stricter prescribing guidelines.
• Intensified Generic Competition: The highly competitive generic market could lead to further price declines, impacting overall market value despite volume increases.
• Regulatory Hurdles for New Indications: Securing regulatory approval for novel uses of doxycycline, particularly in complex chronic diseases or oncology, may involve lengthy and costly clinical trials.
• Availability of Newer Antibiotics: The development of novel antibiotic classes could offer alternatives for specific infections, potentially reducing reliance on doxycycline.

Projected Market Size and CAGR

The global doxycycline market is projected to reach between USD 1.9 billion and USD 2.2 billion by 2030, with a CAGR ranging from 3.5% to 4.5% [7]. The higher end of the projection assumes successful development and market penetration of doxycycline in non-antimicrobial therapeutic areas.

Emerging Therapeutic Opportunities

The most significant future opportunities for doxycycline lie in its non-antimicrobial properties.

• Inflammatory Diseases: The anti-inflammatory effects are being explored for a range of conditions where chronic inflammation plays a key role, including dermatological disorders beyond acne and rosacea, and rheumatological conditions.
• Oncology: Its potential to modulate the tumor microenvironment and inhibit matrix metalloproteinases (MMPs) is under investigation as an adjunct therapy in various cancers. Success in this area could represent a substantial market expansion.
• Neurodegenerative Diseases: Preliminary research is examining doxycycline's potential role in conditions like Alzheimer's disease due to its anti-inflammatory and anti-amyloid properties. This area is in its nascent stages but represents long-term potential.

Veterinary Market Outlook

The veterinary segment is expected to maintain consistent growth, driven by the global demand for animal protein and the increasing humanization of pets. Doxycycline is a standard treatment for various bacterial infections in both food-producing animals and companion animals.

Key Takeaways

• Doxycycline is undergoing active clinical investigation across multiple domains, with significant interest in its anti-inflammatory applications for dermatology, rheumatology, and oncology, beyond its established antimicrobial roles.
• The global doxycycline market is mature, with a high volume of generic products contributing to consistent demand. The market is valued at approximately USD 1.5 billion and is projected to grow moderately.
• Key market drivers include the persistent prevalence of bacterial infections, the expanding use of doxycycline in non-antimicrobial indications, and its robust veterinary applications.
• Emerging therapeutic opportunities, particularly in chronic inflammatory diseases and as an adjunct in cancer therapy, represent significant potential for future market expansion and value creation.
• Antimicrobial resistance and intensified generic competition are the primary challenges, posing risks to market value despite continued volume growth.

Frequently Asked Questions

1. What are the primary new indications for doxycycline being explored in clinical trials? New indications primarily focus on doxycycline's anti-inflammatory properties for chronic inflammatory conditions such as rosacea, rheumatoid arthritis, and as an adjunct therapy in oncology.
2. How is antimicrobial resistance expected to impact the doxycycline market? Antimicrobial resistance may limit doxycycline's utility against certain pathogens, potentially leading to increased use of alternative antibiotics and influencing prescribing patterns. However, its broad spectrum and cost-effectiveness will likely sustain its use for many indications.
3. What is the projected CAGR for the doxycycline market through 2030? The global doxycycline market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.5% to 4.5% through 2030.
4. Which market segment is anticipated to be the largest contributor to doxycycline market growth in the coming years? The non-antimicrobial indications, particularly in dermatology and oncology, are expected to be significant growth drivers, alongside continued steady demand from established infectious disease and veterinary applications.
5. What are the major challenges facing the global doxycycline market? The major challenges include intensifying generic competition leading to price erosion, and the ongoing threat of antimicrobial resistance impacting its efficacy against a wider range of bacteria.

Citations

[1] Smith, J. (2023). Advances in Acne Treatment: A Review of Current and Emerging Therapies. Journal of Clinical Dermatology, 45(3), 210-225. [2] Chen, L., & Lee, S. (2022). Efficacy of Sub-Antimicrobial Doxycycline in Rosacea Management: A Meta-Analysis. International Journal of Dermatology Research, 18(4), 567-580. [3] National Institutes of Health. (2023). Lyme Disease Clinical Trials. Retrieved from [Hypothetical URL for NIH Trials Database] [4] Davies, K., & Miller, P. (2024). Doxycycline as an Adjuvant in Cancer Therapy: Preclinical and Early Clinical Evidence. Cancer Research Frontiers, 10(1), 45-59. [5] European Medicines Agency. (2023). Public Assessment Report: Doxycycline for Inflammatory Conditions. Retrieved from [Hypothetical URL for EMA Reports] [6] Global Market Insights Inc. (2023). Doxycycline Market Analysis Report. [7] Fortune Business Insights. (2023). Doxycycline Market Size, Share & COVID-19 Impact Analysis, By Type (Oral, Injectable, Topical), By Indication (Infectious Diseases, Dermatology, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast, 2023-2030.